Collateral Therapeutics (CLTX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Collateral Therapeutics (CLTX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (6)	5/21/1999 9:30:00 AM
From: Silver Knife	Read Replies (1) of 35

CLTX mentioned in Forbes 5/31/99 forbes.com Collateral Therapeutics, San Diego, CA;founded 1995; www.collateralthx.com; 1998 revenues:$5.4M; projected 1999 revenues: $8M Collateral Therapeutics specializes in the newest and hottest area of gene therapy: treatments for cardiovascular diseases, the number-one killer in the United States. With the help of big pharma giant Schering-Plough, Collateral Therapeutics is running the first placebo-controlled, double-blind trials for nonsurgical angiogenesis, a noninvasive way to stimulate the formation of blood vessels. In this process, a deactivated virus carries a growth hormone to the heart cells; this stimulates the creation of new blood vessels, allowing blood to bypass the blocked vessels, thus restoring normal blood flow.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next